MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
12.50
+1.91
+17.99%
Opening 12:39 12/08 EST
OPEN
10.89
PREV CLOSE
10.59
HIGH
12.53
LOW
10.56
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
13.78
52 WEEK LOW
5.68
MARKET CAP
738.16M
P/E (TTM)
-3.3953
1D
5D
1M
3M
1Y
5Y
1D
Cullinan Therapeutics Presents Promising CLN-049 Data
TipRanks · 3h ago
Cullinan Therapeutics shares updated clinical data from Phase 1 study of CLN-049
TipRanks · 3h ago
Cullinan Therapeutics Reports CLN-049 Monotherapy Efficacy With Multiple Complete Responses And Durable Activity In Heavily Pretreated R/R AML Patients, Achieves 31% CR/CRh At Highest Dose, Demonstrates Favorable Safety Across Doses; Phase 1 Data Presented At ASH 2025
Benzinga · 3h ago
CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACY
Reuters · 3h ago
Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML
Reuters · 4h ago
Weekly Report: what happened at CGEM last week (1201-1205)?
Weekly Report · 9h ago
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Barchart · 10h ago
BTIG Keeps Their Buy Rating on Cullinan Management (CGEM)
TipRanks · 5d ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.